BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Singapore Approves Wegovy as First Treatment for MASH with Liver Fibrosis

ESSENCE trial data showed 63% of participants receiving semaglutide achieved steatohepatitis resolution without worsening of liver fibrosis, compared with ...

September 23, 2026 | News

NewAmsterdam, Menarini Secure EU Approval for Obicetrapib-Based Ubeslo and Evlarco

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-s...

September 23, 2026 | News

Bestzyme Completes World’s First Automated Smart Production Line for Sweet Proteins

Bestzyme, a synthetic biology company under GenScript Biotech, announced the completion of the world's first dedicated, automated smart production li...

September 23, 2026 | News

Gan&Lee Doses First Participant in Phase I Trial of Once-Weekly Oral GLP-1 Candidate GZC8072

Gan&Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan&Lee) announced that the first participant has been dosed in a First-In-Human (FIH...

September 11, 2026 | News

Ascletis Begins US Phase I Trial of Oral Amylin Agonist ASC36 for Obesity

- This trial marks the fourth Phase I peptide study for Ascletis this year. - ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at ste...

September 10, 2026 | News

Genprex Selects Andelyn Biosciences to Scale Up AAV Gene Therapy for Diabetes

Andelyn Biosciences, a leading contract development and manufacturing organization, announced that Genprex, Inc. has selected Andelyn to support scale-up m...

September 03, 2026 | News

Ascletis Doses First Patient in Global Phase III Programme for Oral GLP-1 Obesity Drug ASC30

- Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and...

September 01, 2026 | News

SIBIONICS Showcases AI-Powered GS3 Glucose Monitoring, Advances Integrated Diabetes Care at Melbourne Congress

SIBIONICS showcased its sensor innovation and AI-powered glucose monitoring at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress, held in Melbour...

September 01, 2026 | News

South Korea’s Hanmi Pharm Licenses Obesity Drug HM17321 to Genentech in $2.3B Deal

HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including ob...

August 25, 2026 | News

Kodiak Sciences Enrols First Patients in Phase III ALTO Trial of KSI-501 for Diabetic Macular Edema

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializin...

August 12, 2026 | News

Biocon Launches Interchangeable YESAFILI Biosimilar to EYLEA in the U.S.

Yesafili™ (aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg Potential ...

August 06, 2026 | News

Ascletis Initiates Global Phase III Trial for Oral GLP-1 Obesity Drug ASC30

-Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight acr...

August 05, 2026 | News

Torrey Pines Medicine Raises Angel Funding to Advance Ultra-Long-Acting Peptide Therapies

Led by Lotus Lake Capital, the financing will accelerate the development of TPM004, a differentiated ultra-long-acting amylin/calcitonin receptor dual agon...

July 30, 2026 | News

APAC's Peptide-Capacity Gamble

For most of pharmaceutical history, the hard part was finding a molecule that worked. The GLP-1 class inverted that logic. The science arrived first &mdash...

July 09, 2026 | Analysis

Stay Connected